- Home
- ZVRA vs CSTL Comparison
ZVRA vs CSTL Comparison
Compare ZVRA & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVRA
- CSTL
- Stock Information
- Founded
- ZVRA 2006
- CSTL 2007
- Country
- ZVRA United States
- CSTL United States
- Employees
- ZVRA N/A
- CSTL N/A
- Industry
- ZVRA Biotechnology: Pharmaceutical Preparations
- CSTL Medical Specialities
- Sector
- ZVRA Health Care
- CSTL Health Care
- Exchange
- ZVRA Nasdaq
- CSTL Nasdaq
- Market Cap
- ZVRA 481.7M
- CSTL 456.2M
- IPO Year
- ZVRA 2015
- CSTL 2019
- Fundamental
- Price
- ZVRA $12.34
- CSTL $19.66
- Analyst Decision
- ZVRA Strong Buy
- CSTL Strong Buy
- Analyst Count
- ZVRA 9
- CSTL 6
- Target Price
- ZVRA $23.25
- CSTL $37.67
- AVG Volume (30 Days)
- ZVRA 1.0M
- CSTL 442.5K
- Earning Date
- ZVRA 08-12-2025
- CSTL 08-04-2025
- Dividend Yield
- ZVRA N/A
- CSTL N/A
- EPS Growth
- ZVRA N/A
- CSTL N/A
- EPS
- ZVRA N/A
- CSTL N/A
- Revenue
- ZVRA $40,588,000.00
- CSTL $347,083,000.00
- Revenue This Year
- ZVRA $292.31
- CSTL N/A
- Revenue Next Year
- ZVRA $78.65
- CSTL $1.36
- P/E Ratio
- ZVRA N/A
- CSTL N/A
- Revenue Growth
- ZVRA 46.47
- CSTL 38.43
- 52 Week Low
- ZVRA $5.45
- CSTL $15.45
- 52 Week High
- ZVRA $12.55
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- ZVRA 84.06
- CSTL 55.46
- Support Level
- ZVRA $8.58
- CSTL $19.21
- Resistance Level
- ZVRA $12.37
- CSTL $20.26
- Average True Range (ATR)
- ZVRA 0.51
- CSTL 0.64
- MACD
- ZVRA 0.31
- CSTL -0.05
- Stochastic Oscillator
- ZVRA 98.47
- CSTL 60.34
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.